{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:28:01Z","timestamp":1789738081012,"version":"4.0.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The role of tumor genomic profiling is rapidly growing as it results in targeted, personalized, cancer therapy. Though routinely used in clinical practice, there are no data exploring the reliability of genomic data obtained from spine metastases samples often leading to multiple biopsies in clinical practice. This study compares the genomic tumor landscape between spinal metastases and the corresponding primary tumors as well as between spinal metastases and visceral metastases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Spine tumor samples, obtained for routine clinical care from 2013 to 2019, were analyzed using MSK-IMPACT, a next-generation sequencing assay. These samples were matched to primary or metastatic tumors from the corresponding patients. A concordance rate for genomic alterations was calculated for matching sample pairs within patients for the primary and spinal metastatic tumor samples as well as for the matching sample pairs within patients for the spinal and visceral metastases. For a more robust and clinically relevant estimate of concordance, subgroup analyses of previously established driver mutations specific to the main primary tumor histologies were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighty-four patients contributed next-generation sequencing data from a spinal metastasis and at least one other site of disease: 54 from the primary tumor, 39 had genomic tumor data from another, nonspinal metastasis, 12 patients participated in both subsets. For the cohort of matched primary tumors and spinal metastases (n = 54) comprised of mixed histologies, we found an average concordance rate of 96.97% for all genetic events, 97.17% for mutations, 100% for fusions, 89.81% for deletions, and 97.01% for amplifications across all matched samples. Notably, &amp;gt;25% of patients harbored at least one genetic variant between samples tested, though not specifically for known driver mutations. The average concordance rate of driver mutations was 96.99% for prostate cancer, 95.69% (P = .0004513) for lung cancer, and 96.43% for breast cancer. An average concordance of 99.02% was calculated for all genetic events between spine metastases and non-spinal metastases (n = 41) and, more specifically, a concordance rate of 98.91% was calculated between spine metastases and liver metastases (n = 12) which was the largest represented group of nonspine metastases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Sequencing data performed on spine tumor samples demonstrate a high concordance rate for genetic alterations between the primary tumor and spinal metastasis as well as between spinal metastases and other, visceral metastases, particularly for driver mutations. Spine tumor samples may be reliably used for genomic-based decision making in cancer care, particularly for prostate, NSCLC, and breast cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noac009","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T20:15:47Z","timestamp":1641413747000},"page":"1090-1100","source":"Crossref","is-referenced-by-count":13,"title":["Clinical reliability of genomic data obtained from spinal metastatic tumor samples"],"prefix":"10.1093","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4037-8716","authenticated-orcid":false,"given":"Ori","family":"Barzilai","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Memorial Sloan-Kettering Cancer Center , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1258-6112","authenticated-orcid":false,"given":"Anne S","family":"Reiner","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Laufer","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, New York University School of Medicine , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H","family":"Bilsky","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Memorial Sloan-Kettering Cancer Center , New York, New York , USA"},{"name":"Department of Neurological Surgery, Weill Cornell Medical College , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"issue":"6900","key":"2022070112574013000_CIT0001","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/418823a","article-title":"A progression puzzle","volume":"418","author":"Bernards","year":"2002","journal-title":"Nature"},{"issue":"11","key":"2022070112574013000_CIT0002","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"issue":"22","key":"2022070112574013000_CIT0003","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med."},{"issue":"283","key":"2022070112574013000_CIT0004","doi-asserted-by":"crossref","first-page":"283ra254","DOI":"10.1126\/scitranslmed.aaa1408","article-title":"Clonal status of actionable driver events and the timing of mutational processes in cancer evolution","volume":"7","author":"McGranahan","year":"2015","journal-title":"Sci Transl Med."},{"issue":"1","key":"2022070112574013000_CIT0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ccell.2019.12.004","article-title":"Cancer genome evolutionary trajectories in metastasis","volume":"37","author":"Birkbak","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"2022070112574013000_CIT0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007632-199001000-00001","article-title":"Spinal metastases: the obvious, the occult, and the impostors","volume":"15","author":"Wong","year":"1990","journal-title":"Spine (Phila Pa 1976)"},{"issue":"27","key":"2022070112574013000_CIT0007","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJM199212313272714","article-title":"Metastases and spinal cord compression","volume":"327","author":"Sinson","year":"1992","journal-title":"N Engl J Med."},{"issue":"2 Suppl","key":"2022070112574013000_CIT0008","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.1177\/2192568219895265","article-title":"The role of minimal access surgery in the treatment of spinal metastatic tumors","volume":"10","author":"Barzilai","year":"2020","journal-title":"Global Spine J."},{"issue":"3","key":"2022070112574013000_CIT0009","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn."},{"issue":"2","key":"2022070112574013000_CIT0010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","article-title":"Comprehensive characterization of cancer driver genes and mutations","volume":"173","author":"Bailey","year":"2018","journal-title":"Cell"},{"issue":"2","key":"2022070112574013000_CIT0011","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pilie","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"issue":"6","key":"2022070112574013000_CIT0012","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"issue":"6","key":"2022070112574013000_CIT0013","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med."},{"issue":"1","key":"2022070112574013000_CIT0014","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12967-017-1125-8","article-title":"Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions","volume":"15","author":"Ivanov","year":"2017","journal-title":"J Transl Med."},{"key":"2022070112574013000_CIT0015","doi-asserted-by":"crossref","first-page":"644472","DOI":"10.3389\/fonc.2021.644472","article-title":"The impact of variant allele frequency in EGFR Mutated NSCLC patients on targeted therapy","volume":"11","author":"Friedlaender","year":"2021","journal-title":"Front Oncol."},{"key":"2022070112574013000_CIT0016","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fonc.2019.00851","article-title":"Standardization of sequencing coverage depth in NGS: recommendation for detection of clonal and subclonal mutations in cancer diagnostics","volume":"9","author":"Petrackova","year":"2019","journal-title":"Front Oncol."},{"issue":"7239","key":"2022070112574013000_CIT0017","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"issue":"7","key":"2022070112574013000_CIT0018","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41588-019-0423-x","article-title":"Quantitative evidence for early metastatic seeding in colorectal cancer","volume":"51","author":"Hu","year":"2019","journal-title":"Nat Genet."},{"issue":"9","key":"2022070112574013000_CIT0019","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.celrep.2019.04.098","article-title":"The genomic and immune landscapes of lethal metastatic breast cancer","volume":"27","author":"De Mattos-Arruda","year":"2019","journal-title":"Cell Rep"},{"issue":"5","key":"2022070112574013000_CIT0020","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol."},{"issue":"5","key":"2022070112574013000_CIT0021","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet."},{"issue":"2","key":"2022070112574013000_CIT0022","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"5","key":"2022070112574013000_CIT0023","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41588-018-0086-z","article-title":"Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets","volume":"50","author":"Wedge","year":"2018","journal-title":"Nat Genet."},{"issue":"3","key":"2022070112574013000_CIT0024","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic hallmarks and structural variation in metastatic prostate cancer","volume":"174","author":"Quigley","year":"2018","journal-title":"Cell"},{"issue":"5","key":"2022070112574013000_CIT0025","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/2192568217710911","article-title":"Systematic review of the outcomes of surgical treatment of prostate metastases to the spine","volume":"7","author":"Clarke","year":"2017","journal-title":"Global Spine J"},{"issue":"5","key":"2022070112574013000_CIT0026","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer."},{"issue":"10066","key":"2022070112574013000_CIT0027","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"key":"2022070112574013000_CIT0028","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jocn.2016.05.023","article-title":"Emerging and established clinical, histopathological and molecular parametric prognostic factors for metastatic spine disease secondary to lung cancer: Helping surgeons make decisions","volume":"34","author":"Batista","year":"2016","journal-title":"J Clin Neurosci."},{"issue":"1","key":"2022070112574013000_CIT0029","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/PAI.0000000000000725","article-title":"Epidermal growth factor receptor gene mutation status in primary lung adenocarcinoma and corresponding bone metastases","volume":"28","author":"Shi","year":"2020","journal-title":"Appl Immunohistochem Mol Morphol."},{"issue":"1","key":"2022070112574013000_CIT0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clon.2014.09.014","article-title":"Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer","volume":"27","author":"Wang","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2022070112574013000_CIT0031","author":"American Cancer Society. Cancer facts & figures 2021. Atlanta, Ga: American Cancer Society; 2021"},{"issue":"7418","key":"2022070112574013000_CIT0032","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas N","year":"2012","journal-title":"Nature"},{"issue":"3","key":"2022070112574013000_CIT0033","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14737159.2018.1439382","article-title":"The breast tumor microenvironment: role in cancer development, progression and response to therapy","volume":"18","author":"Mittal","year":"2018","journal-title":"Expert Rev Mol Diagn."},{"issue":"21","key":"2022070112574013000_CIT0034","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1200\/JCO.2017.72.7362","article-title":"Integrating evidence-based medicine for treatment of spinal metastases into a decision framework: neurologic, oncologic, mechanicals stability, and systemic disease","volume":"35","author":"Barzilai","year":"2017","journal-title":"J Clin Oncol."},{"issue":"7","key":"2022070112574013000_CIT0035","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41576-019-0114-6","article-title":"Resolving genetic heterogeneity in cancer","volume":"20","author":"Turajlic","year":"2019","journal-title":"Nat Rev Genet."},{"issue":"1","key":"2022070112574013000_CIT0036","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","article-title":"Biological and therapeutic impact of intratumor heterogeneity in cancer evolution","volume":"27","author":"McGranahan","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"2022070112574013000_CIT0037","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.trecan.2015.07.009","article-title":"Surviving at a distance: organ-specific metastasis","volume":"1","author":"Obenauf","year":"2015","journal-title":"Trends Cancer"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noac009\/42500840\/noac009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/7\/1090\/44371601\/noac009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/7\/1090\/44371601\/noac009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T12:58:16Z","timestamp":1656680296000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/24\/7\/1090\/6499453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,1,6]]},"published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noac009","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,1,6]]}}}